BerGenBio (BGBIO) is a clinical-stage biopharmaceutical company - Martin Olin , Chief Executive Officer, Bergenbio 00:00:00
Martin Olin joined BerGenBio as Chief Executive Officer in 2021. Mr. Olin has more than 20 years of experience as an executive in the pharmaceutical and biotechnology industries. He previously served as CEO of Symphogen, a biotechnology company focused on the development of protein drugs based on recombinant monoclonal antibody mixtures, acquired by Servier in 2020.